Skip to Main Content

The kidney is the primary organ for excretion of uric acid. Patients with proximal tubular dysfunction have decreased excretion of uric acid and are more prone to gouty arthritis attacks. Depending on the pH and uric acid concentration, deposition can occur in the tubules, the interstitium, or the urinary tract. The more alkaline pH of the interstitium causes urate salt deposition, whereas the acidic environment of the tubules and urinary tract causes uric acid crystal deposition at high concentrations.

Three disorders are commonly seen: (1) uric acid nephrolithiasis, (2) acute uric acid nephropathy, and (3) chronic urate nephropathy. Kidney dysfunction with uric acid nephrolithiasis stems from obstructive physiology. Acute uric acid nephropathy presents similarly to acute tubulointerstitial nephritis with direct toxicity from uric acid crystals. Chronic urate nephropathy is caused by deposition of urate crystals in the alkaline medium of the interstitium; this can lead to fibrosis and atrophy. Epidemiologically, hyperuricemia and gout have been associated with worse cardiovascular outcomes.

Treatment between gouty attacks involves avoidance of food and drugs causing hyperuricemia (see Chapter 20), aggressive hydration, and urate-lowering therapy (such as with allopurinol and febuxostat). The three disorders mentioned above are seen in both “overproducers” and “underexcretors” of uric acid. The latter situation may seem counterintuitive; however, these patients have hyperacidic urine, which explains the deposition of relatively insoluble uric acid crystals. For those with uric acid nephrolithiasis, fluid intake should exceed 3 L/day, and use of a urinary alkalinizing agent can be considered. Patients with hyperuricemia who do not have a history of gout or uric acid nephrolithiasis should not receive urate-lowering therapy.

Johnson  RJ  et al. Hyperuricemia, acute and chronic kidney disease, hypertension, and cardiovascular disease: report of a scientific workshop organized by the National Kidney Foundation. Am J Kidney Dis. 2018 Jun;71(6):851–65.
[PubMed: 29496260]
Singh  JA  et al. Comparative effectiveness of allopurinol versus febuxostat for preventing incident renal disease in older adults: an analysis of Medicare claims data. Ann Rheum Dis. 2017 Oct;76(10):1669–78.
[PubMed: 28584186]
Vargas-Santos  AB  et al. Management of gout and hyperuricemia in CKD. Am J Kidney Dis. 2017 Sep;70(3):422–39.
[PubMed: 28456346]

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.